
Product Data Sheet

Product Name: RORyt Inverse agonist 10

Cat. No.: GC68411

Chemical Properties

Cas. No. 2413986-35-1

Formula $C_{25}H_{26}F_6N_6O_3$ M.Wt 572.5

Solubility Storage 4°C, away from moisture and light

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT, or blue ice upon request.

Structure

Background

RORyt Inverse agonist 10 is a potent and orally bioavailable **RORyt (retinoic acid receptor-related orphan nuclear receptor gamma t)** inverse agonist, with an **IC₅₀** of 51 nM. RORyt is a major transcription factor of genes related to psoriasis pathogenesis such as IL-17A, IL-22, and IL-23R^[1]

RORyt Inverse agonist 10 has a good liver microsome stability (human $CL_{int}=0.010$ mL/min/mg, mouse $CL_{int}=0.030$ mL/min/mg)^[1].

RORyt Inverse agonist 10 suppresses the IL-17A production in a dose-dependent manner with an **IC₅₀** of 130 nM in a human whole-blood assay^[1].

RORyt Inverse agonist 10 (3-100 mg/kg; p.o.) shows robust and dose-dependent inhibitory effect on the IL-17A production in mouse IL-18/23-induced cytokine expression model^[1].

RORyt Inverse agonist 10 (1.145 mg/kg; p.o.) shows a high AUC of 15000 nM*h and $t_{1/2}$ of 3.6 hours^[1].

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

Animal Model: C57/BL6 male mice, mouse IL-18/23-induced cytokine expression model^[1]

Dosage: 3 mg/kg, 10 mg/kg, 30 mg/kg, 100 mg/kg

Administration: Oral administration

Result: Significantly inhibited the IL-17A production in a dose-dependent manner.

Animal Model: Mice^[1]

Dosage: 1.145 mg/kg (Pharmacokinetic Analysis)

Administration: Oral administration

Result: AUC=15000 nM*h, $t_{1/2}$ =3.6 hours.

[1]. Ryota Nakajima, et al. Discovery of [1,2,4]Triazolo[1,5- a]pyridine Derivatives as Potent and Orally Bioavailable ROR γ t Inverse Agonists. ACS Med Chem Lett. 2020 Feb 27;11(4):528-534.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA